期刊文献+

埃索美拉唑镁治疗消化性溃疡出血的临床疗效观察 被引量:8

暂未订购
导出
摘要 目的:观察埃索美拉唑镁治疗消化性溃疡出血的临床疗效及副作用。方法:将118例消化性溃疡出血的患者随机分成观察组62例和对照组56例,所有患者均常规给予一般止血剂静滴或(和)输血、扩容等抗休克治疗。在以上常规治疗基础上观察组加用埃索美拉唑镁静滴治疗,对照组加用奥美拉唑静滴治疗。观察两组给药后3d及5d的临床疗效。结果:观察组的总有效率为100%,对照组为85.7%。两组比较差异有统计学意义(P<0.01)。观察组副作用小。结论:注射用埃索美拉唑镁治疗消化性溃疡出血的疗效显著明显优于奥美拉唑,且无明显毒副反应,安全性好。
作者 刘红英
出处 《中外医学研究》 2012年第13期14-15,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献6

二级参考文献27

  • 1乔玉山.中西医结合治疗消化性溃疡并出血41例总结[J].湖南中医杂志,2004,20(5):9-10. 被引量:1
  • 2何学春.中西医结合治疗急性上消化道出血52例[J].湖南中医杂志,2005,21(4):37-37. 被引量:2
  • 3罗金键.注射用奥美拉唑治疗消化性溃疡出血疗效观察[J].医药论坛杂志,2007,28(15):65-66. 被引量:4
  • 4陈灏珠.实用内科学[M].11版.北京:人民卫生出版社,2003: 814-833.
  • 5赵盘珠.消化性溃疡合并上消化道出血的治疗体会[J].中国医药导报,2007,4(10Z):134-135. 被引量:58
  • 6Andrew S.Pathogenesis of Non-steroidal Anti-inflammatory Drugs-related Upper Gastrointestinal Toxicity[J].Am J Med,1998,105(5A):10S216S.
  • 7Garcia Rodriguez L A,Jick H.Risk of Upper Gastrointestinal Bleeding and Perforation Associated with Individual Non-steroidal Anti2inflammatory Drugs[J].Lancet,1994,343(8900):769-772.
  • 8Hawkey C J,Nasdal J,Wilson I,et al.Relative Contribution of Mucosal Injury and Helicobacter Pylori in the Development of Gastroduodenal Lesions in Patients Taking Non-steroidal Anti2inflammatory Drugs[J].Gut,2002,51:336-343.
  • 9Wu C Y,Poon S K,Chen G H,et al.Interaction Between Helicobacter Pylori and Non2steroidal Anti-inflammatory Drugs in Pep Tic Ulcers Bleeding[J].Scand J Gastroenterol,1999,34:234-237.
  • 10Huang J Q,Sfidhar S,Hunt R H.Role of Helicobacter Pylori Infection and Non-steroidal Anti-inflammatory Drugs in Peptic-ulcer Disease:Meta-analysis[J].Lancet,2002,359:14-22.

共引文献84

同被引文献58

  • 1赵龙,李丽,陈辉,杨伟兴,肖国辉.国产艾司奥美拉唑针剂对非食管静脉曲张出血的疗效分析[J].世界临床医学,2017,11(22):88-88. 被引量:1
  • 2胡伏莲.消化性溃疡发病机制的现代理念[J].中华消化杂志,2005,25(3):189-190. 被引量:257
  • 3王成永,时军,王姝婧.奥美拉唑肠溶微丸制备及其质量影响因素探讨[J].安徽医药,2005,9(7):493-493. 被引量:8
  • 4谢玉民.埃索美拉唑对十二指肠球溃疡合并幽门螺杆菌感染的治疗[J].世界华人消化杂志,2006,14(4):450-452. 被引量:17
  • 5Hassan-Alin M ,Andersson T,Bredberg E ,et al. Pharmcokinectics of es- omeprazole after oral and intravenous administration of single and repeated doses to healthy subjects[J]. Eur J Clin Pharmacol, 2000,56(9/10) : 665-670.
  • 6Johnson DA, Benjamin SB,Vakil NB,et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms : a randomized, double-blind, placebo-controlled study of efficacy and safety[J]. Am J Gastroenterol, 2001,96 ( 1 ) : 27-34.
  • 7Wilder-Smith CH, Rhss K, Bondarov P, et al. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v. : results of a randomized study[J]. Aliment Pharmacol Ther, 2004, 20(10) : 1099-1104.
  • 8Rhss K,Lind T,Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastfic acid control than lansoprazole 30 mg,omeprazole 20 mg,pantoprazole 40 mg and rabeprazole 20 mg in patients with gastrooe- sophageal reflux symptoms[J]. Eur J Clin Pharmacol, 2004,60 (8) : 531- 539.
  • 9萧树东,郑青.Hp治疗指征及国内外的推荐方案[J].中华消化杂志,2003,23(9):555-556.
  • 10Miner P, Katz P, Chen Y, et al. Gastri acid control with esomeprazole, lansoprazole, omeprazole, pantoprazone, and rabeprazone:a five-way crossover study [J]. Am J Gastroenterol, 2003, 98:2616 - 2620.

引证文献8

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部